Canopus BioPharma Incorporated (CBIA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Canopus BioPharma Incorporated (CBIA) trades at $0.0001 with AI Score 50/100 (Grade B). Canopus BioPharma Incorporated operates as a pharmaceutical research company, focusing on providing products and assay methods for infectious, cancer, and addiction diseases. Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for CBIA: CBIA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CBIA against Financial Services peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CBIA: 1/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Canopus BioPharma Incorporated (CBIA) Financial Services Profile
Canopus BioPharma Incorporated, a pharmaceutical research company in the financial services sector, focuses on providing pharmaceutical products and assay methods for infectious, cancer, and addiction diseases. Operating as a shell company, it navigates a competitive landscape with limited financial visibility, as reflected by its negative P/E ratio.
What Is the Investment Thesis for CBIA?
Canopus BioPharma Incorporated, with a market capitalization of $0.00B and a negative P/E ratio of -0.01, presents a high-risk, high-reward investment profile. The company's focus on pharmaceutical products and assay methods for infectious, cancer, and addiction diseases offers potential for significant growth if its research and development efforts yield successful and marketable products. However, the company's high beta of 9.40 indicates substantial volatility. Key catalysts include successful clinical trials and regulatory approvals. The absence of a dividend yield reflects a focus on reinvesting earnings into research and development. Investors should carefully assess the company's financial stability and the competitive landscape before considering an investment.
Based on FMP financials and quantitative analysis
CBIA Key Highlights
Market capitalization of $0.00B indicating a micro-cap company.
- Negative P/E ratio of -0.01 reflecting current losses or minimal earnings.
- Beta of 9.40 indicating high volatility compared to the market.
- No dividend yield suggesting retained earnings are reinvested in the business.
- Focus on pharmaceutical products and assay methods for infectious, cancer, and addiction diseases.
Who Are CBIA's Competitors?
CBIA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| APHD Apogee 21 Holdings, Inc. | $1.10 | +0.00% | $19.7M | 49 |
| NIHL New Infinity Holdings, Ltd. | $0.10 | +0.00% | $10.8M | 62 |
| LRGR Luminar Media Group, Inc. | $0.50 | +47.06% | $22.4M | 68 |
| CLAYU Chavant Capital Acquisition Corp. | $10.97 | +18.34% | $27.5M | 62 |
| CLAY Chavant Capital Acquisition Corp. | $10.66 | +6.39% | $29.6M | 62 |
| INACU Indigo Acquisition Corp. | $12.08 | +16.94% | $34.9M | 60 |
| HHGC HHG Capital Corporation | $11.12 | +0.09% | $56.2M | 63 |
| MAAQ Mana Capital Acquisition Corp. | $5.99 | -24.18% | $57.0M | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CBIA's Key Strengths?
Focus on specialized pharmaceutical products.
- Research and development capabilities.
- Diverse product offerings including antivirals and oncology products.
- Potential for growth in niche markets.
What Are CBIA's Weaknesses?
Limited financial resources.
- High beta indicating significant volatility.
- Dependence on research and development success.
- Small market capitalization.
What Could Drive CBIA Stock Higher?
Research and development of new pharmaceutical products for infectious, cancer, and addiction diseases.
- Potential for successful clinical trials and regulatory approvals.
- Expansion into new therapeutic areas.
- Strategic partnerships with larger pharmaceutical companies.
- Commercialization of bio-barcode assay technology.
What Are the Key Risks for CBIA?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Limited financial resources and high beta indicating significant volatility.
- Regulatory hurdles and compliance costs.
- Competition from larger pharmaceutical companies.
- Risk of unsuccessful clinical trials.
- Market volatility and economic downturns.
What Are the Growth Opportunities for CBIA?
- Expansion of Oncology Product Line: The global oncology market is projected to reach $286.6 billion by 2028, growing at a CAGR of 11.8%. Canopus BioPharma can capitalize on this growth by expanding its oncology product line through research and development of novel cancer treatments and therapies. Successful clinical trials and regulatory approvals in this area could significantly increase the company's market value and revenue streams. This growth opportunity requires substantial investment in research and development and strategic partnerships with other pharmaceutical companies.
- Development of Antiviral Products: The antiviral drug market is expected to grow, driven by the emergence of new viral threats and the increasing prevalence of existing viral infections. Canopus BioPharma can focus on developing innovative antiviral products to address unmet medical needs. The market is projected to reach $60 billion by 2027. Success in this area would depend on the company's ability to develop effective and safe antiviral drugs, navigate regulatory hurdles, and establish strong distribution channels.
- Advancement of Bio-Barcode Assay Technology: Bio-barcode assays are emerging as a promising technology for early disease detection and diagnosis. Canopus BioPharma can invest in further developing and commercializing its bio-barcode assay technology for various applications, including cancer diagnostics and infectious disease detection. The market for bio-barcode assays is expected to grow significantly in the coming years, driven by the increasing demand for rapid and accurate diagnostic tools. This growth opportunity requires collaboration with research institutions and healthcare providers.
- Commercialization of Camelidae Blood Products: Camelidae blood products, such as nanobodies, have potential applications in various therapeutic areas, including cancer and autoimmune diseases. Canopus BioPharma can explore the commercialization of camelidae blood products through research and development of novel therapies and diagnostic tools. The market for nanobody-based therapeutics is expected to grow substantially in the coming years. Success in this area would depend on the company's ability to develop effective and safe nanobody-based products and secure regulatory approvals.
- Expansion into Nutraceuticals Market: The global nutraceuticals market is projected to reach $441.7 billion by 2026, driven by increasing consumer awareness of the health benefits of nutraceuticals and the growing demand for natural health products. Canopus BioPharma can expand its product portfolio to include nutraceuticals targeting various health conditions, such as immune support and cardiovascular health. This growth opportunity requires strategic partnerships with nutraceutical manufacturers and distributors, as well as compliance with regulatory requirements for nutraceutical products.
What Are CBIA's Competitive Advantages?
- Proprietary pharmaceutical products.
- Specialized assay methods.
- Focus on niche therapeutic areas.
- Research and development capabilities.
What Does CBIA Do?
Founded in 1996 as Canopus Corporation and renamed Canopus BioPharma Incorporated in 2007, the company is based in Santa Monica, California. Canopus BioPharma focuses on developing and providing pharmaceutical products and assay methods targeting infectious, cancer, and addiction diseases. Its product offerings include antivirals, radiation protection products, oncology products, bio-barcode assays, camelidae blood products, and neutraceuticals. The company aims to address critical medical needs through research and development in these therapeutic areas. As a pharmaceutical research company, Canopus BioPharma operates within a highly regulated and competitive environment, requiring continuous innovation and strategic partnerships to sustain growth and market relevance. The company's evolution reflects its commitment to advancing pharmaceutical solutions for challenging health conditions, positioning itself as a provider of specialized products and services in the biopharmaceutical sector.
What Products and Services Does CBIA Offer?
- Provides pharmaceutical products for infectious diseases.
- Offers pharmaceutical products for cancer.
- Develops pharmaceutical products for addiction diseases.
- Supplies antivirals.
- Provides radiation protection products.
- Offers bio-barcode assays.
- Supplies camelidae blood products.
- Offers neutraceuticals.
How Does CBIA Make Money?
- Develops and researches pharmaceutical products.
- Sells pharmaceutical products to patients.
- Generates revenue through product sales.
- Focuses on niche markets like infectious, cancer, and addiction diseases.
What Industry Does CBIA Operate In?
Canopus BioPharma Incorporated operates within the shell companies industry, a segment characterized by high risk and speculative investments. The broader financial services sector is subject to regulatory scrutiny and market volatility. The pharmaceutical research market is driven by innovation and the need for new treatments for diseases like cancer and infectious diseases. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms. Canopus BioPharma's success depends on its ability to develop and commercialize its products effectively.
Who Are CBIA's Key Customers?
- Patients suffering from infectious diseases.
- Patients suffering from cancer.
- Patients suffering from addiction diseases.
- Healthcare providers.
- Research institutions.
Key Financial Metrics
Its free cash flow yield is -1.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.24 means current liabilities exceed short-term assets, a liquidity point worth watching.
Canopus BioPharma Incorporated (CBIA) Valuation Context
Relative to its peer group, CBIA's quantitative score of 50/100 is below the peer average of 61/100.
Company Profile
Canopus BioPharma Incorporated operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Las Vegas, US. The company is led by CEO Justin de Four. CBIA has traded publicly since 1999.
Financial Health
Canopus BioPharma Incorporated's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
CBIA Financials
Bull Case vs Bear Case
Bull Case
- Focus on specialized pharmaceutical products.
- Research and development capabilities.
- Diverse product offerings including antivirals and oncology products.
- Potential for growth in niche markets.
Bear Case
- Limited financial resources.
- High beta indicating significant volatility.
- Dependence on research and development success.
- Small market capitalization.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
CBIA Latest News
No recent news available for CBIA.
CBIA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CBIA.
Price Targets
Wall Street price target analysis for CBIA.
CBIA MoonshotScore
What does this score mean?
The MoonshotScore rates CBIA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Classification
Industry Shell CompaniesLeadership: Patrick T. Prendergast
CEO
Patrick T. Prendergast serves as the CEO of Canopus BioPharma Incorporated. Information regarding his detailed career history, education, and previous roles is not available in the provided data. Further research would be required to provide a comprehensive background on his professional experience and qualifications.
Track Record: Due to the limited information available, it is not possible to provide a detailed track record of Patrick T. Prendergast's achievements, strategic decisions, or company milestones under his leadership. Further research would be necessary to assess his performance and contributions to Canopus BioPharma Incorporated.
CBIA OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Canopus BioPharma Incorporated may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not provide regular financial disclosures, increasing the risk for investors. Investing in OTC Other stocks requires careful due diligence and an understanding of the potential risks involved compared to stocks listed on major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Higher price volatility.
- Potential for fraud or manipulation.
- Lack of regulatory oversight.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with OTC trading.
- Consult with a financial advisor.
- Monitor news and developments related to the company.
- Existence of a physical headquarters.
- Presence of a functional website.
- Availability of contact information.
- Engagement with investors and stakeholders.
- Compliance with basic regulatory requirements.
What Investors Ask About Canopus BioPharma Incorporated (CBIA) — Financial Services
What does the AI Score mean for CBIA?
CBIA holds an AI Score of 50/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Canopus BioPharma Incorporated operates as a pharmaceutical research company, focusing on providing products and assay methods for infectious, cancer, and addiction diseases. The company's …
What does Canopus BioPharma Incorporated do?
Canopus BioPharma Incorporated operates as a pharmaceutical research company focused on developing and providing pharmaceutical products and assay methods for patients suffering from infectious, cancer, and addiction diseases. The company's product offerings include antivirals, radiation protection products, oncology products, bio-barcode assays, camelidae blood products, and neutraceuticals.
What do analysts say about CBIA stock?
There is no available analyst coverage for Canopus BioPharma Incorporated (CBIA) stock. The company's micro-cap status and OTC listing may contribute to the lack of analyst coverage. Investors should conduct their own thorough research and due diligence before considering an investment in CBIA. Key valuation metrics to consider include the company's market capitalization, P/E ratio, and growth potential.
What are the main risks for CBIA?
The main risks for Canopus BioPharma Incorporated include limited financial resources, high volatility as indicated by a beta of 9.40, dependence on successful research and development outcomes, and competition from larger pharmaceutical companies. As an OTC-listed company, CBIA faces additional risks related to liquidity, regulatory oversight, and potential for fraud or manipulation.
How does Canopus BioPharma Incorporated manage its financial risks?
Given the limited financial information available, it is difficult to assess Canopus BioPharma Incorporated's specific risk management strategies. As a small company with a negative P/E ratio, CBIA likely faces significant financial challenges. The company's ability to manage its cash flow, control its expenses, and secure funding for its research and development activities is critical to its survival and growth.
What regulatory challenges does Canopus BioPharma Incorporated face?
As a pharmaceutical research company, Canopus BioPharma Incorporated faces significant regulatory challenges related to the development, testing, and commercialization of its products. The company must comply with regulations set forth by agencies such as the FDA in the United States. These regulations cover various aspects of the pharmaceutical industry, including clinical trials, manufacturing processes, and marketing practices.
What are the key factors to evaluate for CBIA?
Canopus BioPharma Incorporated (CBIA) holds an AI score of 50/100 (moderate). Canopus BioPharma Incorporated, with a market capitalization of $0.00B and a negative P/E ratio of -0.01, presents a high-risk, high-reward investment profile. Not financial advice.
How frequently does CBIA data refresh on this page?
CBIA's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CBIA's recent stock price performance?
Canopus BioPharma Incorporated (CBIA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on specialized pharmaceutical products. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available.
- OTC market carries inherent risks.
- AI analysis pending.